TY - JOUR
T1 - Pyoderma gangrenosum
AU - Eichhorn, Phillip J.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - Pyoderma gangrenosum (PG) is a chronic ulcerative skin disease with striking clinical features that may rarely involve internal organs, particularly the lung, liver, and spleen. Approximately 50% of PG patients have associated inflammatory, immune dysfunction, or neoplastic diseases. The various topical, systemic, and surgical treatment options for PG are reviewed here. Systemic corticosteroids plus immunosuppressive therapy are often required to successfully manage severe cases of PG. Practical treatment strategies are discussed along with their proper monitoring and potential adverse effects. Current treatment methods are empiric, and the optimum treatment regimen for this disorder requires future controlled clinical trials.
AB - Pyoderma gangrenosum (PG) is a chronic ulcerative skin disease with striking clinical features that may rarely involve internal organs, particularly the lung, liver, and spleen. Approximately 50% of PG patients have associated inflammatory, immune dysfunction, or neoplastic diseases. The various topical, systemic, and surgical treatment options for PG are reviewed here. Systemic corticosteroids plus immunosuppressive therapy are often required to successfully manage severe cases of PG. Practical treatment strategies are discussed along with their proper monitoring and potential adverse effects. Current treatment methods are empiric, and the optimum treatment regimen for this disorder requires future controlled clinical trials.
KW - Cyclophosphamide
KW - Cyclosporine A
KW - Mycophenolate mofetil
KW - Pyoderma gangrenosum
KW - Systemic corticosteroids
UR - http://www.scopus.com/inward/record.url?scp=0035005367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035005367&partnerID=8YFLogxK
U2 - 10.1046/j.1529-8019.2001.014002102.x
DO - 10.1046/j.1529-8019.2001.014002102.x
M3 - Review article
AN - SCOPUS:0035005367
SN - 1396-0296
VL - 14
SP - 102
EP - 110
JO - Dermatologic Therapy
JF - Dermatologic Therapy
IS - 2
ER -